Position in PRLD
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$67,541
-$40,690 QoQ
Shares Held
12,672
-83.1% QoQ
Ownership
0.016%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#54
of 75 holders
Holding Since
Mar 2022
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PRLD Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GSA CAPITAL PARTNERS LLP holds $104,909,103 across 164 Biotechnology names. PRLD ranks #150 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IOVA |
Iovance Biotherapeutics, Inc.
|
655,318 | $2,726,122 | |
| 2 | IMVT |
Immunovant, Inc.
|
65,267 | $2,514,737 | |
| 3 | GOSS |
Gossamer Bio, Inc.
|
187,337 | $2,472,846 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
9,419 | $2,305,488 | |
| 5 | CABA |
Cabaletta Bio, Inc.
|
668,563 | $2,079,230 | |
| 6 | MLTX |
MoonLake Immunotherapeutics
|
106,695 | $2,077,351 | |
| 7 | ATYR |
aTYR PHARMA INC
|
3,454,863 | $2,062,553 | |
| 8 | CORT |
Corcept Therapeutics Inc
|
23,257 | $2,022,196 |
All Filings in PRLD
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $67,541 | 12,672 | Shares | Sole | 2026-08-06 | |
| 2025-09-30 | $108,231 | 75,161 | Shares | Sole | 2025-11-07 | |
| 2025-06-30 | $57,744 | 71,378 | Shares | Sole | 2025-07-22 | |
| 2023-09-30 | $218,101 | 70,583 | Shares | Sole | 2023-11-15 | |
| 2023-06-30 | $327,753 | 72,834 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $271,399 | 47,614 | Shares | Sole | 2023-05-12 | |
| 2022-12-31 | $288,718 | 47,801 | Shares | Sole | 2023-02-13 | |
| 2022-09-30 | $358,083 | 54,173 | Shares | Sole | 2022-11-14 | |
| 2022-06-30 | $191,187 | 36,626 | Shares | Sole | 2022-08-09 | |
| 2022-03-31 | $160,086 | 23,201 | Shares | Sole | 2022-05-11 | |
| No filing history on record for this holder in this stock. | ||||||